“Patients need to have a voice, and if someone is not paying attention to the developing science and the risk has not been properly outlined and they couldn’t make an informed decision, then there has to be accountability.”

This was partner Alicia Theuma speaking to The Daily Telegraph for a major investigation into the experiences of women who developed meningiomas after using the contraceptive injection Depo-Provera. Austen Hays is pursuing a group action on behalf of women who developed meningiomas after using Depo-Provera.

The article and video interview examine concerns about the potential risks associated with prolonged use of Depo-Provera’s active ingredient, medroxyprogesterone acetate (MPA), and hear from women who have undergone brain surgery and been left with life-changing health problems.

The women featured in the investigation describe the profound impact their diagnoses and treatment have had on their health, independence, careers and families. Their experiences underline why access to clear information about potential risks matters when people are making decisions about their health.

Alicia tells The Telegraph that Austen Hays is currently speaking to over 400 women, with more continuing to come forward. “They’ve had to completely alter their lives. Lots of people have had to give up work, give up driving, no social or hobbies are undertaken anymore,” she says.

The Telegraph also speaks to associate solicitor Rachel Bright about how guidance differs internationally. Rachel explains that in France, Depo-Provera is now prescribed only where other forms of contraception are unsuitable and patients presenting with symptoms associated with meningioma during treatment are referred for an MRI.

The concerns follow a 2024 study published in the British Medical Journal which found an association between prolonged MPA use and an increased risk of meningioma.

Watch the full video interview with The Daily Telegraph:

Find out more

Austen Hays is currently investigating claims for compensation for those who have been affected by meningioma and have been using Depo-Provera for over a year.

Explore our Depo-Provera investigation